Emergent BioSolutions | EBS - Pre Tax Profit


Emergent BioSolutions reported $-130.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2023.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Lonza CHF 624M 197M Dec/2024
Merck USD -3.53B 6.95B Mar/2026
Moderna USD -1.33B 535M Mar/2026
Myriad Genetics USD 4.6M 3.4M Dec/2025
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pacira USD 5M 4.43M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sanofi EUR 837M 1.17B Jun/2026
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024